PASG Projected Dividend Yield
Passage Bio Inc ( NASDAQ : PASG )Passage Bio is a genetic medicines company focused on developing therapies for monogenic central nervous system disorders. Co. is developing PBGM01, which utilizes a proprietary AAVhu68 capsid for the treatment of GM1 gangliosidosis. Co. is also developing PBFT02, which utilizes an AAV1 capsid for the treatment of frontotemporal dementia-progranulin deficiency. Co. is also developing PBKR03, which utilizes a proprietary AAVhu68 capsid for the treatment of Krabbe disease. Co. has various programs in the research stage under its license agreement with the Trustees of the University of Pennsylvania including: PBML04 for metachromatic leukodystrophy and PBAL05 for amyotrophic lateral sclerosis. 20 YEAR PERFORMANCE RESULTS |
PASG Dividend History Detail PASG Dividend News PASG Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |